BeOne Medicines (NASDAQ:ONC – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.
Insider and Institutional Ownership
48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for BeOne Medicines and Korro Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 1 | 2 | 11 | 2 | 2.88 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
Profitability
This table compares BeOne Medicines and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 8.94% | 12.06% | 6.69% |
| Korro Bio | -1,834.48% | -117.86% | -71.04% |
Volatility and Risk
BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.
Valuation and Earnings
This table compares BeOne Medicines and Korro Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $5.34 billion | 6.61 | $286.93 million | $4.47 | 72.05 |
| Korro Bio | $3.84 million | 39.23 | -$117.26 million | ($11.67) | -0.90 |
BeOne Medicines has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
BeOne Medicines beats Korro Bio on 10 of the 15 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
